Neotherix has been named as one of 40 companies receiving funds from the TSB's research and development investment programme in Regenerative Medicine. Neotherix' proposal, "EktoTherix: development of a regenerative tissue scaffold for repair of surgical excision wounds" was one of 30 successful applications under the Regenerative Medicine Therapeutics Feasibility scheme to which £2.8m has been allocated to explore the feasibility of delivering previously-identified therapeutic candidates into regenerative products. Neotherix will conduct pre-clinical testing on the EktoTherix scaffold and also make initial assessments of the anticipated regulatory pathway in Europe and the US and of the robustness of the current manufacturing process for translation of the product prototype to the clinic.
Commenting on the award to Neotherix, Dr Zahid Latif, Technology Strategy Board lead technologist in Medicines and Healthcare, said "the UK is a world leader in regenerative medicine and we hope that the Technology Strategy Board's extensive support programme will enable our best businesses to flourish. We are delighted to support Neotherix' feasibility study and we look forward to seeing the results of their exciting work."
See the TSB press release .